Research map: Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-Associated Steatohepatitis

Back to the article

Papers in this map

  1. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes · Zobair M. Younossi · 2015 · 11046 citations · Cited by this paper
  2. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial · Lee M. Kaplan · 2026 · 8 citations · Cites this paper
  3. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus · 2020 · Related
  4. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
  5. MRI risk stratification in metabolic dysfunction–associated steatotic liver disease (MASLD): from diffuse liver disease to focal lesions · Gabriela Carboni · 2026 · Cites this paper
  6. WITHDRAWN: Levels of Vitamin D Are Low Before or After Crohn’s disease Is Established? · 2025 · Related
  7. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease · Paul G. Angulo · 2015 · 3025 citations · Cited by this paper
  8. Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review · Sayan Malakar · 2026 · Cites this paper
  9. Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition · 2026 · Related
  10. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease · Chris Estes · 2017 · 2456 citations · Cited by this paper
  11. Letter on ‘Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated MASH Cirrhosis for Fibrosis Regression and MASH Resolution’. Authors' Reply · Matheus Henrique Gonçalves de Souza · 2026 · Cites this paper
  12. Elsewhere in the AGA Journals · 2026 · Related
  13. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease · Vlad Ratziu · 2005 · 2109 citations · Cited by this paper
  14. Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics · Malek Ayoub · 2026 · Cites this paper
  15. Increasing Incidence and Prevalence of Microscopic Colitis in Sweden: A Nationwide Population-Based Cohort Study · 2026 · Related
  16. Mechanisms and disease consequences of nonalcoholic fatty liver disease · Rohit Seth Loomba · 2021 · 2026 citations · Cited by this paper
  17. Association Between Index Adenomas and Advanced Findings at Third Colonoscopy: Data From the New Hampshire Colonoscopy Registry · 2026 · Related
  18. Treatment of NAFLD with diet, physical activity and exercise · Manuel Romero‐Gómez · 2017 · 1360 citations · Cited by this paper
  19. Mosaicism in Patients With Colorectal Cancer or Polyposis Syndromes: A Systematic Review · 2020 · Related
  20. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH · Rohit Seth Loomba · 2023 · 505 citations · Cited by this paper
  21. Metabolic Dysfunction and Alcohol-Associated Steatotic Liver Disease in Women: Epidemiology, Natural History, and Clinical Outcomes · 2026 · Related
  22. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials · Beth A. Davison · 2020 · 449 citations · Cited by this paper
  23. Long-Term Outcomes After Endoscopic Submucosal Dissection for T1 Colorectal Cancer: A Multicenter Prospective Study · 2026 · Related
  24. Challenges and opportunities in NASH drug development · Stephen A. Harrison · 2023 · 362 citations · Cited by this paper
  25. Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies · 2026 · Related
  26. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort · Stephen A. Harrison · 2021 · 293 citations · Cited by this paper
  27. Metabolic dysfunction-associated steatotic liver disease in adults · Daniel Q. Huang · 2025 · 286 citations · Cited by this paper
  28. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis · Jonathan G. Stine · 2020 · 282 citations · Cited by this paper
  29. Impact of non-invasive biomarkers on hepatology practice: Past, present and future · Quentin Mark Anstee · 2022 · 224 citations · Cited by this paper
  30. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib · Saumya Jayakumar · 2018 · 210 citations · Cited by this paper
  31. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis · Mazen Noureddin · 2021 · 203 citations · Cited by this paper
  32. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study · Stephen A. Harrison · 2024 · 169 citations · Cited by this paper
  33. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study · Mary Eugenia Rinella · 2021 · 161 citations · Cited by this paper
  34. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis · Monica A. Tincopa · 2023 · 158 citations · Cited by this paper
  35. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis · Rohit Seth Loomba · 2021 · 130 citations · Cited by this paper
  36. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH · Mazen Noureddin · 2025 · 127 citations · Cited by this paper
  37. New and emerging treatments for metabolic dysfunction-associated steatohepatitis · Monica A. Tincopa · 2024 · 123 citations · Cited by this paper
  38. Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents · Michele Di Martino · 2016 · 99 citations · Cited by this paper
  39. Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis · Matheus Henrique Gonçalves de Souza · 2025 · 99 citations · Cited by this paper

Source: OpenAlex (CC0)